Gene:
MYL3
myosin, light chain 3, alkali; ventricular, skeletal, slow

On ACMG incidental findings list

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.

PharmGKB has no annotated drug labels with pharmacogenomic information for this . If you know of a drug label with PGx, send us a message.

PharmGKB contains no Clinical Variants that meet the highest level of criteria.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

This is a non-comprehensive list of genetic tests with pharmacogenetics relevance, typically submitted by the manufacturer and manually curated by PharmGKB. The information listed is provided for educational purposes only and does not constitute an endorsement of any listed test or manufacturer.

A more complete listing of genetic tests is found at the Genetic Testing Registry (GTR).

PGx Test Variants Assayed Related Drugs?

Overview

Alternate Names:  None
Alternate Symbols:  CMH8; MLC1SB; MLC1V; VLC1
PharmGKB Accession Id: PA31381

Details

Cytogenetic Location: chr3 : p21.31 - p21.2
GP mRNA Boundary: chr3 : 46899357 - 46904973
GP Gene Boundary: chr3 : 46896357 - 46914973
Strand: minus
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

Curated Information ?

Curated Information ?

Publications related to MYL3: 1

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in medicine : official journal of the American College of Medical Genetics. 2013. Green Robert C, et al. PubMed

LinkOuts

Entrez Gene:
4634
OMIM:
160790
608751
UCSC Genome Browser:
NM_000258
RefSeq RNA:
NM_000258
RefSeq Protein:
NP_000249
RefSeq DNA:
AC_000046
AC_000135
NC_000003
NG_007555
NT_022517
NW_001838877
NW_921651
UniProtKB:
MYL3_HUMAN (P08590)
Ensembl:
ENSG00000160808
GenAtlas:
MYL3
GeneCard:
MYL3
MutDB:
MYL3
ALFRED:
LO028127U
HuGE:
MYL3
Comparative Toxicogenomics Database:
4634
ModBase:
P08590
HumanCyc Gene:
HS08538
HGNC:
7584

Common Searches